Brand-name GLP-1 medications, prescribed after a full metabolic and hormonal evaluation, with your body composition and muscle mass tracked along the way. The medication is one tool in your plan, not the entire plan.
The evaluation is the first step for our hormone, weight, and longevity programs. Looking for everyday primary care? Direct Primary Care members enroll online, no evaluation needed.
Weight loss is not just about willpower or calories. It’s driven by hormones, insulin signaling, appetite regulation, inflammation, stress, sleep, and how your metabolism adapts over time.
When appetite signaling is regulated, weight loss becomes more manageable and less mentally exhausting, allowing lifestyle changes to actually work. At Venture Wellness, GLP-based care is not prescribed in isolation. It’s part of a broader metabolic strategy that considers insulin function, hormones, nutrition, muscle preservation, and long-term sustainability.
Medication and dosing are determined at your evaluation, based on your metabolic profile, health history, and how your body responds, not a standard starting dose applied to everyone. Our patients often find success at lower doses, because we are also working on the other things that drive weight: hormones, nutritional markers, and overall metabolic health.
Prescribed as Wegovy for weight management. Ozempic is the same medication, approved for type 2 diabetes.
Prescribed as Zepbound for weight management. Mounjaro is the same medication, approved for type 2 diabetes.
An oral GLP-1 approved by the FDA in April 2026 for weight management. It can be taken at any time of day, with no food or water restrictions.
Other oral weight-loss medications are also used, depending on your medical evaluation and your preference. GLP-1 medications aren’t right for everyone. We review your history and go over risks and side effects with you before prescribing.
For patients who have coverage for GLP-1 medications and qualify under their insurer’s requirements, we submit a prior authorization to request coverage on your behalf.
Whether you have insurance coverage or will use self-pay also plays a role in choosing a medication, because accessibility matters. Coverage decisions are made by your insurer.
The goal is steady fat loss while preserving muscle mass. We track your body composition and monitor muscle mass through treatment, so your plan can be adjusted if you’re losing muscle along with fat.
That matters for your energy, your strength, and keeping the weight off after treatment.
These injections support the nutrient side of metabolic health. They are not weight-loss medications, and they don’t replace nutrition, activity, or prescribed therapy.
B12 helps your body turn food into energy and supports red blood cell production and nerve function.
A blend of lipotropic nutrients (methionine, inositol, and choline) with B vitamins and L-carnitine. These nutrients take part in how the liver processes fat and how your cells use fat for energy.
Comprehensive intake, labs, and identification of metabolic and hormonal contributors.
A personalized plan that may include medical therapy, nutrition guidance, and behavioral support, based on how your body responds.
Ongoing monitoring and adjustments to protect progress and prevent rebound.
Care adapts as your metabolism, lifestyle, and goals change over time.
We prescribe brand-name GLP-1 medications: semaglutide (Wegovy or Ozempic), tirzepatide (Zepbound or Mounjaro), and Foundayo (orforglipron), a once-daily pill. Oral weight-loss medications are also used depending on your medical evaluation and preference. Selection is based on your metabolic profile, health history, and how your body responds.
Yes. Foundayo (orforglipron) is a once-daily GLP-1 pill approved by the FDA in April 2026 for weight management. It can be taken at any time of day without food or water restrictions. Whether a pill or a weekly injection suits you better is part of your evaluation.
Yes. If you have coverage for GLP-1 medications and qualify under your insurer’s requirements, we submit a prior authorization to request coverage on your behalf. Coverage decisions are made by your insurer.
Medical weight loss may be appropriate if you struggle with weight despite consistent effort. Additional criteria for metabolic management include insulin resistance, diabetes, metabolic dysfunction, or a BMI of 27 or higher with related health concerns.
You don’t have to have a lot to lose. We also treat patients who are close to their goal and can’t move the last 5 to 15 pounds, where the aim is body recomposition: losing fat while keeping or building muscle, which we track with body composition measurements rather than the scale alone.
Treatment options are determined at your evaluation.
Most online platforms write a prescription after a short questionnaire. At Venture Wellness, your weight loss plan is built on a comprehensive metabolic and hormonal evaluation, and we track your body composition and muscle mass as you go. The medication is one tool in your metabolic health plan, not the entire plan.
Most patients notice meaningful changes within the first 4–8 weeks. Significant, sustainable progress typically develops over 3–6 months as your plan is fine-tuned to your response. Results vary from person to person.
Without addressing the underlying metabolic contributors, weight regain is common after stopping any GLP-1 medication. That’s why our program focuses on metabolic function, hormonal balance, muscle preservation, and sustainable habits alongside the medication, so the results have a foundation to stand on.
They support the nutrient side of metabolic health. B12 helps your body turn food into energy. Lipo-Mino-C combines methionine, inositol, and choline with B vitamins and L-carnitine, nutrients that take part in how the liver processes fat and how cells use fat for energy. They complement your plan; they are not weight-loss medications.
We care for patients from Midlothian, Richmond, Chesterfield County, Bon Air, Powhatan, and Chester, and across the greater Richmond area. Visits are in person at our Midlothian office, and by telehealth when it’s clinically appropriate.
Updated September 2026
